(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
Abu Dhabi Crown Prince Sheikh Khaled bin Mohamed Al Nahyan took the helm of a $300 billion sovereign wealth fund which has become central to building the infrastructure needed to override Iran’s stranglehold over the Strait of Hormuz. The fund is now likely to spend tens of billions of dollars more on new port infrastructure outside the embattled strait, people familiar with the matter said. Bloomberg's Alex Dooler reports. (Source: Bloomberg)
(RTTNews) - Galderma (GALD) announced new three-year results from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in patients with moderate-to-severe atopic dermatitis.
OpenAI aims to raise at least $30 billion from investors in a new round of funding, according to people familiar with the matter. The company is seeking a valuation of around $1.4 trillion, not including the money raised, said the people. This comes after the artificial intelligence startup pushed back its plans for an initial public offering. Bloomberg's Neil Campling reports. (Source: Bloomberg)
(RTTNews) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-
(RTTNews) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-
(RTTNews) - Dyne Therapeutics (DYNE) announced on Tuesday additional one-year clinical data from the Phase 1/2 ACHIEVE trial of investigational Z-basivarsen showing sustained functional improvements across multiple measures in patients with myotonic dystrophy type 1.
(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Wednesday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA under priority review for fenebrutinib in both relapsing and primary progressi